Skip to main content
≥99.0% HPLC Verified • SEPA Bank & Crypto • Min. Order €220
Metabolic Research 3 min read

Cagrilintide vs Retatrutide: Amylin/Calcitonin Receptors vs Triple Incretin Agonism

Compiled & reviewed by SwissLab Peptide Biochemistry Editorial Desk — Preclinical Literature & Receptor Mechanism Review Desk
Editorial Standards
Analytical Summary

Cagrilintide (AM833, CAS 1415456-99-3) activates brainstem amylin (AMY1R–3R) and calcitonin (CTR) receptors via a cyclic disulfide architecture, operating independently of the GLP-1R/GIPR/GCGR incretin pathways targeted by Retatrutide, Tirzepatide, and Semaglutide.

Key Research Takeaways
  • Cagrilintide is a 37-residue acylated amylin analogue with a critical Cys2–Cys7 intramolecular disulfide bridge and C20 fatty diacid.
  • Amylin receptors are heterodimers of the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1–3).
  • Unlike Retatrutide or Tirzepatide, Cagrilintide acts outside the incretin GPCR family—enabling additive co-formulation research with Semaglutide (CagriSema) or Tirzepatide.
  • Cagrilintide requires mildly acidic buffer control (pH ~4.0) to prevent amyloidogenic fibril aggregation during aqueous bench storage.
Analytical & Handling Reference Matrix
Cagrilintide CAS / MW 1415456-99-3 | 4409.04 g/mol | Cys2–Cys7 Disulfide
Primary Receptors Calcitonin Receptor (CTR) + RAMP1/2/3 (AMY1R–3R)
Retatrutide CAS / MW 2381089-83-2 | 4731.33 g/mol | Linear Acylated 39-aa
Incretin Comparison Semaglutide (GLP-1R) | Tirzepatide (GLP-1R/GIPR) | Retatrutide (Triple)
Fibrillation Prevention Proline substitutions at 25/28/29 + low-agitation acidic/neutral prep
Analytical Verification ≥99.0% RP-HPLC + ESI-MS disulfide closure verification (-2 Da)

1. Structural Chemistry of Cagrilintide (AM833)

Cagrilintide (CAS 1415456-99-3, MW 4409.04 g/mol) is a 37-amino acid acylated analogue of human amylin (islet amyloid polypeptide, IAPP). Native human amylin aggregates rapidly into insoluble β-sheet fibrils in aqueous solution. Cagrilintide overcomes fibrillation through rat-derived proline substitutions (Pro25, Pro28, Pro29), an N-terminal C20 fatty-diacid moiety attached via a γ-glutamic acid spacer for albumin binding, and a conserved Cys2–Cys7 intramolecular disulfide loop essential for receptor recognition.

2. Cagrilintide vs Retatrutide: Orthogonal Receptor Families

Comparing Cagrilintide vs Retatrutide contrasts two completely distinct neuroendocrine signaling axes. Retatrutide engages Class B incretin/glucagon GPCRs (GLP-1R, GIPR, GCGR) expressed across pancreatic islets, adipose tissue, and hepatocytes. Cagrilintide acts as a dual amylin and calcitonin receptor agonist (DACRA), binding CTR/RAMP1–3 heterodimers localized in the area postrema and nucleus tractus solitarius to modulate gastric emptying and satiety cascades independently of incretin signaling.

3. Co-Administration Models: Cagrilintide + Semaglutide vs Tirzepatide

Because amylin receptors do not compete with GLP-1R or GIPR binding sites, researchers study co-formulations such as Cagrilintide + Semaglutide alongside single-molecule multi-agonists like Tirzepatide and Retatrutide. Note a critical formulation constraint: Cagrilintide achieves optimal chemical stability near pH 4.0, whereas Semaglutide is formulated near pH 7.4—meaning separate stock vials or carefully validated dual-chamber reconstitution protocols prevent pH-induced deamidation or precipitation.

4. Disulfide Integrity & Reconstitution Controls for Cagrilintide

Never expose Cagrilintide to reducing agents (DTT, TCEP) or alkaline buffers above pH 8.0, which cleave the Cys2–Cys7 disulfide bridge and abolish CTR/AMY receptor potency. Equilibrate sealed lyophilized vials inside a desiccator before slow-wall diluent addition, avoid vortexing to prevent interfacial fibrillation, and store reconstituted stocks refrigerated at 2°C–8°C.

Peer-Reviewed References & Analytical Standards

  1. Kruse T. et al. (2021). Development of Cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry, 64(15), 11183–11194. [PMID: 34288673 ↗]
  2. Frias J.P. et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg (CagriSema). The Lancet, 402(10403), 720–730. [PMID: 37364590 ↗]
  3. Coskun T. et al. (2022). LY3437943 (Retatrutide), a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 34(9), 1234–1247. [PMID: 35985340 ↗]

Referenced Laboratory Research Reagents

Batch-verified SwissLab catalog entries cited in this monograph

All 66 Compounds →
Laboratory Compliance & Handling Protocol

All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.

Related Research Monographs

All monographs (44)

Your Research Cart

0 items selected • Min. order €220

SEPA Bank Transfer & Crypto (BTC, ETH, USDT, USDC, SOL, XMR)
Min €220

Your cart is empty

Browse our catalog of research peptides and reagents (minimum order €220).

Browse Catalog